Fredun Pharmaceuticals Board of Directors

Get the latest insights into the leadership at Fredun Pharmaceuticals. Learn about the experienced professionals guiding the company's strategy and governance.

NamePosition
Dr.(Mrs.) Daulat N Medhora Chairman & Jt. M. D
Mr. Fredun Medhora Managing Director & CFO
Mr. Nariman Medhora Non Executive Director
Dr. Rohinton Kanga Ind. Non-Executive Director
Dr. Aspi Raimalwala Ind. Non-Executive Director
Mrs. Daisy D�souza Ind. Non-Executive Director

Fredun Pharmaceuticals Share price

FREDUN

1270

19.90 (1.59%)
Last updated on 4 Sep, 2025 | 15:28 IST
BUYSELL
Today's High

1312.20

Today's Low

1220.00

52 Week Low

635.00

52 Week High

1329.00

The current prices are delayed, login to your account for live prices

Fredun Pharmaceuticals FAQs

The board at Fredun Pharmaceuticals consists of experienced professionals, including Dr.(Mrs.) Daulat N Medhora , Mr. Fredun Medhora , and others, overseeing the company’s strategic and corporate governance.

Directors at Fredun Pharmaceuticals are typically nominated by the Nomination and Remuneration Committee and approved by shareholders, adhering to regulatory and governance standards. While this is the standard procedure, the exact process may differ depending on the company’s internal policies and governance framework.

As of the latest update, Dr.(Mrs.) Daulat N Medhora is the current chairman at Fredun Pharmaceuticals.

Executive directors at Fredun Pharmaceuticals are involved in day-to-day operations, while non-executive directors, including independents, provide oversight and strategic input. While this distinction is generally followed, the specific responsibilities of executive and non-executive directors may vary based on the company’s organisational structure and governance practices.

Yes, Fredun Pharmaceuticals adheres to all applicable SEBI and Companies Act provisions related to board structure, diversity, and independence.

At Fredun Pharmaceuticals, board members usually serve fixed terms as outlined in the company’s charter or governance policy, commonly ranging between three to five years, with the possibility of renewal based on performance, shareholder approval, and regulatory norms.